Tokolyse

Werner Rath

doi:10.1055/a-1068-7370

Frauenheilkunde up2date, Table of Contents

Frauenheilkunde up2date 2021; 15(02): 119-137
DOI: 10.1055/a-1068-7370

Geburtshilfe und Perinatalmedizin

Tokolyse

Werner Rath

Abstract

All articles of this category

Die medikamentöse Wehenhemmung (Tokolyse) gehört nach der Geburtseinleitung zu den häufigsten Maßnahmen in der Geburtshilfe. Unsicherheiten bestehen vor allem hinsichtlich der Indikation zur Tokolyse. Bisher gibt es nicht das für Mutter und Kind „ideale“ Tokolytikum. Die Erhaltungstokolyse ist eine Einzelfallentscheidung im Spannungsfeld zwischen Evidenz und klinischer Praxis.

Schlüsselwörter

Pathophysiologie - Indikation - Kontraindikation - Evidenz - Tokolytika

Full Text

References

Literatur
1 Zeitling J, Szamolusha K, Drewnick N. et al. Preterm birth time trends in Europe, a study of 19 countries. Br J Obstet Gynaecol 2013; 120: 1356-1365
2 IQTIG: Institut für Qualitätssicherung und Transparenz im Gesundheitswesen 2018. Basisauswertung zum Erfassungsjahr 2017: Geburtshilfe. Im Internet (Stand: 03.08.2020): http://www.iqtig.org
3 Vogel IP, Chawanpaiboon S, Moller AB. et al. The global epidemiology of preterm birth. Best Pract Res Clin Obstet Gynaecol 2018; 52: 3-12
4 AWMF-Leitlinie (S2k): Prävention und Therapie der Frühgeburt 2019. Im Internet (Stand: 05.08.2020): https://www.awmf.org/uploads/tx-szleitlinien/015-025l-s2k
5 Romero R, Dey SK, Fischer SJ. Preterm labor: one syndrome, many causes. Science 2014; 345: 760-765
6 Syhes L, Bennett PP. Efficacy of progesterone for prevention of preterm birth. Best Pract Res Clin Obstet Gynecol 2018;
7 Kuon JR, Abele H, Berger R. et al. Progesterone for prevention of preterm birth – evidence-based indications. Z Gebh Neonatal 2015; 219: 125-135
8 Berger R, Kienast C. Molekulare Grundlage der Frühgeburt. In: Liedtke C, Rody A. Hrsg. Molekulare Gynäkologie und Geburtshilfe. Berlin, Heidelberg: Springer; 2016: 61-68
9 Eloritz MA, Wang Z, Chien EK. et al. A new model for inflammation-induced preterm birth. Am J Pathol 2003; 163: 2103-2111
10 Han CS, Schatz F, Lockward CJ. Abruption-associated prematurity. Clin Perinatol 2011; 38: 407-421
11 Kim YM, Bujold E, Chaiworapongsa T. et al. Failure of physiology transformation of the spiral arteries in patients with preterm labor and intact membranes. Am J Obstet Gynecol 2003; 189: 1663-1669
12 ACOG Practice Bulletin No. 171. Management of preterm labour. Obstet Gynecol 2016; 128: e155-e164
13 Hackney DN, Olson-Chen C, Thomberg LL. What do we know above the natural outcomes of preterm labour? A systematic review and meta-analysis of women without tocolysis in preterm labour. Paediatr Perinat Epidemiol 2013; 27: 452-460
14 Nijman TAJ, van Vliet EOG, Koullali B. et al. Antepartum and intrapartum interventions to prevent preterm birth and its sequelae. Semin Fetal Neonatal Med 2016; 21: 121-128
15 Kagan KO, Sonek J. How to measure the cervix length?. Ultrasound Obstet Gynecol 2015;
16 Onderoglu LS. Digital examination and transperineal ultrasonographic measurement of cervical length to assess risk of preterm delivery. Int J Gynaecol Obstet 1997; 59: 223-228
17 De Franco EA, Lewis DF, Odibo AO. Improving the screening accuracy for preterm labour: is the combination of fetal fibronectin and cervical length in symptomatic patients a useful predictor of preterm birth? A systematic review. Am J Obstet Gynecol 2013; 208: 233.e1-233.e6
18 Society for Maternal-Fetal Medicine (SMFM). Mc Intosh J, Feltovich H. et al. The role of routine cervical length screening in selected high- and low-risk women with preterm birth prevention. Am J Obstet Gynecol 2016; 215: B2-B7
19 De Renzo GC, Roura LC, Facchinetti F. et al. Preterm labor and birth management: Recommendations from the European Association of Perinatal Medicine. J Matern Fetal Neonatal Med 2017; 30: 2011-2030
20 Melchor JC, Khalil A, Wing D. et al. Prediction of preterm delivery in symptomatic women using PAMG-1, fetal fibronectin and phIGFBP-1 tests: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2018; 52: 442-451
21 van Baaren GJ, Vis JY, Wilms FF. et al. Predictive value of cervical length measurement and fibronectin testing in threatened preterm labor. Obstet Gynecol 2014; 123: 1185-1192
22 Berghella V, Saccone G. Fetal fibronectin testing for prevention of preterm birth in singleton pregnancies with threatened preterm labor: a systematic review and metaanalysis of randomized controlled trials. Am J Obstet Gynecol 2016; 215: 431-438
23 van Baaren GJ, Vis JY, Grobman WA. et al. Cost-effectiveness analysis of cervical length measurement and fibronectin testing in women with threatened labor. Am J Obstet Gynecol 2013; 209: 436.e1-436.e8
24 Lange TS, Roos C, Bloemenkamp KW. et al. Impact of a randomized trial on maintenance tocolysis on length of hospital admission of women with threatened preterm labor in the Netherlands. Eur J Obstet Gynecol Reprod Biol 2015; 186: 8-11
25 Rath W, Kehl S. Akuttokolyse – eine kritische Analyse evidenzbasierter Daten. Geburtshilfe Frauenheilkd 2018; 78: 1245-1255
26 NICE Guideline. Preterm labour and birth 2015. Im Internet (Stand: 05.08.2020): http://www.nice.org.uk/guidance/ng25
27 Navathe R, Berghella V. Tocolysis for acute preterm labour: Where have we been, where are we now, and where are we going?. Am J Perinatol 2016; 33: 229-235
28 Haas DM, Imperiale TF, Kirkpatrick PR. et al. Tocolytic therapy: a meta-analysis and decision analysis. Obstet Gynecol 2009; 113: 585-594
29 Haas DM, Caldwell DM, Kirkpatrick PR. et al. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. Br Med J 2012; 345: e6226
30 Neilson JP, West HM, Dowswell T. Betamimetics for inhibiting preterm labour. Cochrane Database Syst Rev 2014; (02) CD004352
31 de Heus R, Mol BW, Erwich JJ. et al. Adverse drug reactions to tocolytic treatment for preterm labour: prospective cohort study. Br Med J 2009; 338: b744
32 Anotayanonth S, Subhedar NV, Neilson JP, Harigopal S. Betamimetics for inhibiting preterm labour. Cochrane Database Syst Rev 2004; (04) CD004352
33 Herzog S, Cunze T, Martin M. et al. Pulsatile vs. continuous parenteral tocolysis: comparison of side effects. Eur J Obstet Gynecol Reprod Biol 1999; 85: 199-206
34 Conde-Agudelo A, Romero R. Transdermal nitroglycerin for the treatment of preterm labour: a systematic review and meta-analysis. Am J Obstet Gynecol 2013; 209: 551.e1-551.e18
35 Duckitt K, Thornton S, OʼDonnovan OP, Dowswell T. Nitric oxide donors for treating preterm labour. Cochrane Database Syst Rev 2014; (05) CD002860
36 Reinebrant HE, Pileggi-Castro C, Romero CLT. et al. Cyclo-oxygenase (COX) inhibitors for treating preterm labour. Cochrane Database Syst Rev 2015; (06) CD001992
37 Sandrock JC, Grobman WA, Garbour SE. The effect of short-term indomethacin therapy on amniotic fluid volume. Am J Obstet Gynecol 2005; 192: 1443-1445
38 Hammers AL, Sanchez-Romero L, Kaunitz AM. Antenatal exposure to indomethacin increased the risk of severe intraventricular haemorrhage, necrotizing enterocolitis, and periventricular leukomalacia: a systematic review with metaanalysis. Am J Obstet Gynecol 2015; 212: 505.e1-505.e13
39 Turan OM, Driscall C, Cetinkaya-Demir B. et al. Prolonged early antenatal indometacin exposure is safe for fetus and neonate. J Matern-Fetal Neonatal Med 2019;
40 Vogel JP, Oladapo OT, Manu A. et al. New WHO recommendations to improve the outcomes of preterm birth. Lancet Glob Health 2015; 3: e589
41 Crowther CA, Brown J, Mc Kinlay CJD. et al. Magnesium sulphate for preventing preterm birth in threatened labour. Cochrane Database Syst Rev 2014; (08) CD001060
42 Lewis DF. Magnesium sulfate: the first-line tocolytic. Obstet Gynecol Clin North Am 2005; 113: 485-500
43 Lyell DJ, Pullen K, Campbell L. et al. Magnesium sulphate compared with Nifedipine for acute tocolysis of preterm labor. Obstet Gynecol 2007; 110: 61-67
44 Xiao C, Gangal M, Abenhaim HA. Effect of magnesium sulfate and nifedipine on the risk of developing pulmonary edema in preterm births. J Perinatal Med 2014; 42: 585-588
45 Flenady V, Wojcieszek AM, Papatsonis DNM. et al. Calcium channel blockers for inhibiting preterm labour and birth. Cochrane Database Syst Rev 2014; (06) CD002255
46 van Vliet EOG, Nijman TAJ, Schuit E. et al. Nifedipine versus atosiban for threatened preterm birth (APOSTEL III): a multicentre, randomised controlled trial. Lancet 2016; 387: 2117-2124
47 Oei SG. Calcium channel blockers for tocolysis: A review of their role and safety following reports of serious adverse events. Eur J Obstet Gynecol Reprod Biol 2006; 126: 137-145
48 Khan K, Zamora J, Lamont RF. et al. Safety concerns for the use of calcium channel blockers in pregnancy for the treatment of spontaneous preterm labour and hypertension: a systematic review and meta-regression analysis. J Matern Fetal Neonatal Med 2010; 23: 1020-1038
49 Sentilhes L, Senat M-V, Ancel PY. et al. Prevention of spontaneous preterm birth: Guidelines for clinical practice from the French College of Gynaecologists and Obstetricians (CNGOF). Eur J Obstet Gynecol Reprod Biol 2017; 210: 217-224
50 Flenady V, Reinebrant HE, Lieley HG. et al. Oxytocin receptor antagonists for inhibiting preterm labour. Cochrane Database Syst Rev 2014; (06) CD004452
51 Nonnenmacher A, Hopp H, Dudenhausen J. Wirksamkeit und Sicherheit von Atosiban vs. pulsatiler Applikation von Fenoterol bei der Behandlung vorzeitiger Wehen. Z Geburtsh Neonatol 2009; 213: 201-206
52 Royal College of Obstetrics and Gynaecologists (RCOG). Green-top guideline 2011, No. 1b. Tocolysis for women in preterm labour. Im Internet (Stand: 05.08.2020): https://www.wis.dom.wales.nhs.uk/openedoc/296835
53 Vogel IP, Nardin JM, Dowswell T. et al. Combination of tocolytic agents for inhibitory labour. Cochrane Database Syst Rev 2014; (07) CD006169
54 Rath W, Kuon R-J. Progesteron- effektiv zur Wehenhemmung und zur Erhaltungstokolyse nach Wehenstopp?. Geburtshilfe Frauenheilkd 2019; 79: 834-843
55 MacKeen AD, Seibel-Seaman J, Muhammad J. et al. Tocolytical for preterm premature rupture of membranes. Cochrane Database Syst Rev 2014; (02) CD007062
56 Miyazaki C, Moreno Garcia R, Ota E. et al. Tocolysis for inhibiting preterm birth in extremely preterm birth, multiple gestations and in growth-restricted fetuses: a systematic review and meta-analysis. Reproductive Health 2016; 13: 7
57 Yamasmit W, Chaithongwongwatthana S, Tolosa JE. et al. Prophylactic oral betamimetics for reducing preterm birth in women with a twin pregnancy. Cochrane Database Syst Rev 2015; (12) CD004733
58 Stelzl P, Kehl S, Rath W. Maintenance tocolysis: a reappraisal of clinical evidence. Arch Gynecol Obstet 2019; 300: 1189-1199 doi:10.1007/s00404-019-05313-7
59 Gaunekar NN, Rama P, Crowther CA. Maintenance therapy with calcium channel blocker for preventing preterm birth after threatened labour. Cochrane Database Syst Rev 2013; (10) CD004071
60 van Vliet E, Dijkema G, Schuit E. et al. Nifedipine maintenance tocolysis and perinatal outcome, an individual participant data meta-analysis. Br J Obstet Gynaecol 2016; 123: 1753-1760
61 Han S, Crowther CA, Moore V. Magnesium maintenance therapy for preventing preterm birth after threatened preterm labour. Cochrane Database Syst Rev 2013; (05) CD000940
62 Suhag A, Saccone G, Berghella V. Vaginal progesterone for maintenance tocolysis: a systematic review and metaanalysis of randomised trials. Obstet Gynecol 2015; 213: 479-487
63 Eke AC, Chalaen T, Shuker G. et al. A systematic review and meta-analysis of progesterone use for maintenance tocolysis after preterm labour in women with intact membranes. Int J Gynecol Obstet 2016; 132: 11-16
64 Palacio M, Rontoni S, Sanchez-Romero I. et al. Progesterones and maintenance treatment in arrested preterm labour: a systematic review and meta-analysis. Obstet Gynecol 2016; 128: 989-1006
65 Wood S, Radi Y, Tang S. et al. Progesterone in women with arrested premature labour – a report of randomised clinical trials and updated meta-analysis. BMC Pregnancy Childbirth 2017; 17: 258
66 Sosa CG, Althabe F, Beliton JM. et al. Bed rest in singleton pregnancies for preventing preterm birth. Cochrane Database Syst Rev 2015; (03) CD003581
67 da Silva Lopes K, Takemoto Y, Ota E. et al. Bed rest with and without hospitalisation in multiple pregnancy for improving perinatal outcomes. Cochrane Database Syst Rev 2017; (03) CD012031